---
title: "MolTrace — Executive One-Pager"
subtitle: "AI-Native Scientific Intelligence for Pharmaceutical R&D"
version: "2026-05-28b"
audience: "Pharmaceutical, biotech, CRO, and academic R&D leadership"
length: "Single page (≈500 words)"
---

# MolTrace

### AI-native scientific intelligence for chemistry and pharmaceutical R&D

> *"Every number in your regulatory dossier traces back to its raw spectrum, its processing recipe, its literature citation, and the human who signed it off."*

---

## The Problem in One Paragraph

Routine NMR / LC-MS structure elucidation in pharma still consumes **6–48 hours of analyst time per compound**, leaves no machine-readable chain of custody from raw FID to dossier sentence, and produces evidence that today's tightening regulatory frameworks (FDA AI Credibility 2025, EMA AI reflection paper, ICH Q2(R2)) are increasingly hard to satisfy. The status-quo toolchain — desktop processing apps, spreadsheets, email-attached PDFs — was not designed for the multi-modal, audit-first, reproducible workflow regulators now expect.

## The MolTrace Solution

A multi-tenant SaaS platform with three integrated programs sharing one evidence engine, one immutable raw-data vault, and one provenance layer:

| Program | What it does |
|---|---|
| **SpectraCheck** | 39-layer NMR + MS evidence engine: 1H, 13C, 2D NMR, raw FID (Bruker / Agilent-Varian), HRMS, MS/MS, LC-MS features. Categorises peaks against literature-backed shift windows. Ranks candidates with DP4/DP5-class methods. Includes an opt-in Mestrenova-style GSD detector that has cleared its production promotion gate against three independent reference corpora — NMRShiftDB2, an HMDB-style synthetic corpus, and a 100-fixture real-instrument HMDB corpus (95 % parseable, 93 % solvent auto-detect). |
| **Regulatory Intelligence Hub** | Dossier scaffolding, ICH/FDA/EMA-aligned audit packs, human-in-the-loop release gating, AI-supported question/answer routing. |
| **Reaction Optimization** | Bayesian optimisation, multi-objective response-surface modelling, design-of-experiments under mechanistic constraints, integrated reaction-history provenance. |

## What Makes MolTrace Different

- **Evidence-first.** Every UI claim is one click from its source spectrum file, peak, SMILES, citation, and reviewer.
- **Immutable raw vault.** Vendor archives are SHA-256 hashed on upload and never overwritten; every processing run is a derived, recipe-hashed artifact.
- **Multi-modal by default.** NMR + HRMS + MS/MS + LC-MS are one evidence stack; cross-modal contradictions surface as first-class warnings.
- **Human-in-the-loop, never autonomous.** No regulatory document releases without explicit reviewer signoff — aligned with the FDA AI Credibility Framework (2025) and EMA AI reflection paper.
- **Open-science under the hood.** RDKit, nmrglue, mzML, FastAPI, Next.js — no proprietary file-format lock-in.

## Quantified Outcomes (typical 8-FTE analytical team, 600 analyses/year)

- **5–10×** compression of time-to-structure (minutes vs. hours)
- **60–80 %** reduction in time-to-dossier
- **> 98 %** report-from-raw reproducibility rate
- **Days→minutes** for audit-cycle question turnaround
- **~$300K/year** recouped FTE cost (mid-complexity small-molecule workflows)

## Compliance Posture

SOC 2 Type II · ICH Compliant · GDPR Ready · GxP Validated · ALCOA+ data-integrity primitives baked into every layer of the architecture.

## What's Next

- **Pilot programs** open for pharmaceutical R&D, CRO, and academic analytical groups
- **Integration packages** for Bruker / Agilent / Waters / Thermo instrumentation
- **Regulatory-affairs onboarding** with dedicated FDA AI Credibility Framework mapping

---

**Read the full white paper.** Hybrid (5,700 words), Sales-led (≈4,000 words), and Technical-reviewer (≈7,500 words) variants available. Request access for pilot evaluation, technical due-diligence, or regulatory-affairs briefings.

*© 2026 MolTrace Technologies, Inc.*
